Overview

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

Status:
Completed

Trial end date:
2007-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the blood pressure lowering effect and safety of the triple combination aliskiren / valsartan / HCTZ (300/320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Valsartan